Core Viewpoint - The conference call discusses the positive results of the Phase II study of daridorexant for children with insomnia disorder, indicating potential advancements in pediatric insomnia treatment [2]. Group 1: Company Overview - Idorsia Pharmaceuticals is presenting the results of its daridorexant program, specifically focusing on its application for pediatric insomnia [2]. - Key personnel involved in the presentation include Jean-Paul Clozel, Chairman and Interim CEO, Martine Clozel, Chief Scientific Officer, and Alberto Gimona, Head of Global Clinical Development [2]. Group 2: Study Results - The Phase II study results for daridorexant in children with insomnia disorder were announced positively, suggesting effective treatment options for this demographic [2]. - The drug is currently investigational and has not yet received approval or marketing authorization in any country [3].